The FDA released on Tuesday a new warning about oral contraceptive pills using the drug drospirenone. According to the administration, drugs including Beyaz, Gianvi, Loryna, Ocella, Safyral, Syeda, Yasmin, Yaz, and Zarah, could cause roughly three times the risk of blood clots as those without drospirenone.
The FDA launched a safety inquiry into the pills last year and their report says they have "concluded that drospirenone-containing birth control pills may be associated with a higher risk for blood clots than other progestin-containing pills."
Each of the nine pills will now carry a new warning label explaining the increased risk. The FDA adds, however, that it's still unclear if it was the behavior of some patients taking these drugs that increased the risk:
"The studies also did not account for important patient characteristics (known and unknown) that may influence prescribing and that likely affect the risk of blood clots. For these reasons, it is unclear whether the increased risk seen for blood clots in some of the epidemiologic studies is actually due to drospirenone-containing birth control pills," the FDA adds.
For comments and feedback contact: editorial@rttnews.com
Health News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.